The HLA-II immunopeptidome of SARS-CoV-2

Area of Science:

• Immunology
• Virology
• Vaccine Development

Background:

• Designing effective vaccines against viral outbreaks like COVID-19 requires detailed knowledge of viral immunogens.
• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents complex challenges for vaccine strategies.

Purpose of the Study:

• To identify SARS-CoV-2 peptides naturally processed and presented on human leukocyte antigen-II (HLA-II) complexes.
• To understand the distinct viral protein targets of HLA-I and HLA-II pathways for improved vaccine design.

Main Methods:

• Analysis of SARS-CoV-2 peptides naturally processed and loaded onto HLA-II in infected cells.
• Identification of over 500 unique viral peptides from canonical and overlapping internal open reading frames.
• Colocalization analysis of HLA-II peptides with known CD4+ T cell epitopes in COVID-19 patients.

Main Results:

• Over 500 unique SARS-CoV-2 peptides were identified, including those from structural and nonstructural proteins.
• Most identified HLA-II peptides overlapped with known CD4+ T cell epitopes, including immunodominant regions in the SARS-CoV-2 membrane protein.
• Distinct viral protein targeting was observed between HLA-I and HLA-II pathways, with structural proteins dominating the HLA-II peptidome.

Conclusions:

• The findings reveal distinct HLA-I and HLA-II targeting of SARS-CoV-2 proteins, with structural proteins being key for HLA-II presentation.
• A comprehensive vaccine design incorporating both CD4+ and CD8+ T cell epitopes from multiple viral elements is essential for maximizing vaccine effectiveness against SARS-CoV-2.